Open company graph database — free web & API
Login

Okayama Daipō Pharmaceutical Co., Ltd.

岡山大鵬薬品株式会社
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
205
Related companies
11
§01

Basic information

BASIC
Head office
1775-1, Oki, Kugui, Bizen City, Okayama Prefecture, 705-8555, Japan
Chief executive
Kazuyoshi Shiraishi
Capital
50,000,000
Employees (non-consolidated)
205 people
Employees (consolidated)
205 people
Start date
1992-08-01
End date
§02

Websites

1 DOMAINS
§03

Business

9
Topical Products BusinessOTC Pharmaceutical BusinessContract Manufacturing BusinessManufacturing and sales of generic drugs (authorized generics) centered on anticancer agentsContract manufacturing of 100mL drink formulationsAuthorized Generic BusinessResearch, development, manufacturing, and sales of pharmaceuticals, quasi-drugs, and miscellaneous goodsManufacturing and sales of medicated plastersPharmaceuticals and consumer healthcare products
§04

Related companies

11 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Daipon Pharmaceutical Industries Co., Ltd.
Group Customer
Otsuka Holdings Co., Ltd.
Group
Otsuka Medical Devices Co., Ltd.
Group
Otsuka Warehouse Co., Ltd.
Group
Otsuka Chemical Co., Ltd.
Group
EN Otsuka Pharmaceutical Co., Ltd.
Group
Otsuka Foods Co., Ltd.
Group
Da Peng Pharmaceutical Industrial Co., Ltd.
Group
Nichiban Co., Ltd.
Customer
Daipō Pharmaceutical Co., Ltd.
Shinsei Pharmaceutical Co., Ltd.
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

66 EVENTS

Since its establishment in 1943, Shinsei Pharmaceutical has developed and supplied topical analgesic anti-inflammatory patches and topical steroid preparations to clinical settings.Sources

Shinsei Pharmaceutical Co., Ltd., predecessor of Okayama Daipō Pharmaceutical, was founded in Shinjuku, Tokyo.Sources

Founded: August 26, 1943 (Showa 18)Sources

June 1963: Daipō Pharmaceutical Industrial Co., Ltd. establishedSources

Daipō Pharmaceutical Industrial Co., Ltd. was established.Sources

May 1971: Neopass launched by Daipō Pharmaceutical Industrial Co., Ltd.Sources

Daipō Pharmaceutical Industrial Co., Ltd. began selling 'Neopass'.Sources

June 1975: Headquarters and factory relocated to Ome City, Tokyo.Sources

Moved headquarters and factory to Ome City, Tokyo.Sources

April 1984: Headquarters and factory relocated to Bizen City, Okayama Prefecture (current location).Sources

Moved headquarters and factory to Bizen City, Okayama Prefecture (current location).Sources

September 1990: Daipō Pharmaceutical Industrial Co., Ltd. acquired all shares of Shinsei Pharmaceutical Co., Ltd., becoming a full subsidiary.Sources

Daipō Pharmaceutical Industrial Co., Ltd. acquired all shares of Shinsei Pharmaceutical Co., Ltd., making it a wholly-owned subsidiary.Sources

September 1991: Production of Mesaderm® ointment and cream commenced.Sources

Started manufacturing Mesaderm® ointment and Mesaderm® cream.Sources

August 1, 1992: Established (Heisei 4).Sources

August 1992: Company name changed to Okayama Daipō Pharmaceutical Co., Ltd.Sources

Renamed the company to Okayama Daipō Pharmaceutical Co., Ltd.Sources

May 1994: Production of Mesaderm® lotion commenced.Sources

Started manufacturing Mesaderm® lotion.Sources

July 1996: Production of MS cold ship 'Taihou' and MS warm ship 'Taihou' commenced.Sources

Started manufacturing MS Cold Slip 'Taihou' and MS Warm Slip 'Taihou'.Sources

September 1999: Completion of the OTC pharmaceutical dedicated factory at headquarters.Sources

Completed an OTC pharmaceutical dedicated factory at headquarters.Sources

October 1999: Commencement of manufacturing of "Zapp®".Sources

Started manufacturing Zahapp®.Sources

July 2000: Commencement of manufacturing "Sportsman-Ship® Cool".Sources

Started manufacturing Sportsman-Slip® Cool (sold by Nichiban Co., Ltd.).Sources

September 2001: Release of "Roih Warm Ship TM".Sources

Released Royhi Warm Slip™ (sold by Nichiban Co., Ltd.).Sources

April 2005: Implementation of revised Pharmaceutical Affairs Law; selection of manufacturing and sales business.Sources

With the implementation of the revised Pharmaceutical Affairs Law, chose to engage in manufacturing and sales.Sources

March 2006: Acquisition of Type 1 Pharmaceutical Manufacturing and Sales License.Sources

Obtained a license for Class I pharmaceutical manufacturing and sales.Sources

May 2006: Commencement of manufacturing "FernaBiOn® Papp".Sources

Started manufacturing Fernabion® patch.Sources

November 2006: ISO14001 certification obtained.Sources

ISO 14001 certification obtainedSources

December 2006: Patent obtained for adhesive sheet release paper structure.Sources

Patent obtained for adhesive sheet release paper structureSources

January 2009: Establishment of Otsuka Holdings and consolidation as a consolidated subsidiary.Sources

Establishment of Otsuka Holdings and consolidation as a consolidated subsidiarySources

September 2012: Release of "Roih Warm Ship TM Ferbinac".Sources

Release of "Roih Warmship TM Ferbinaq" (sold by Nichiban Co., Ltd.)Sources

October 2012: Renewal of "Mesaderm®" (cream, lotion).Sources

Renewal of "Mesaderm®" (cream, lotion)Sources

June 2013: Release of Loxoprofen Sodium Tape "Taihou".Sources

Release of "Loxoprofen Sodium Tape 'Taihou'" (sold by Daipō Pharmaceutical Industrial Co., Ltd.)Sources

January 2017: Release of AG of "Yuzel®" (reduced folic acid formulation) and Holinart tablet "Taihou".Sources

Release of Daipō Pharmaceutical's reduced folic acid formulation "Yuzel®" AG and Holinart tablet "Taihou"Sources

February 2017: Release of "Pure Quick S Ointment".Sources

Release of "Pure Quick S Ointment" (sold by Daipō Pharmaceutical Industrial Co., Ltd.)Sources

June 2017: Release of AG of "TS One®" (metabolism antagonist) with "Swan Taihou®" combination OD tablet.Sources

Release of Daipō Pharmaceutical's metabolic antagonist "TSW1®" AG "Swan Taihou® combined OD tablet"Sources

September 2018: Release of "Roih TM Cream Ferbi".Sources

Release of "Roih TM Cream Ferb" (sold by Nichiban Co., Ltd.)Sources

December 2019: Renamed the selling name of "FernaBiOn® Papp" to "Ferbinac Papp 70mg 'Taihou'" as a general name.Sources

Change of the commercial name of "FernaBiOn® Papp" to the generic name "Ferbinaq Papp 70mg 'Taihou'"Sources

January 2020: Commencement of contract manufacturing of "Thiobita®" drink (100mL) series (seller: Daipō Pharmaceutical Industrial Co., Ltd.).Sources

Start of contract manufacturing for the "Chiovita® Drink (100mL)" series (sold by Daipō Pharmaceutical Industrial Co., Ltd.)Sources

September 2021: Release of AG of "Alokix®" (5-HT3 serotonin receptor antagonist antiemetic) "Parosetron IV" and Parosetron IV infusion bag.Sources

Release of Daipō Pharmaceutical's 5-HT3 (serotonin) receptor antagonist antiemetic "Aroxi®" AG "ParoNocetron IV", "ParoNocetron IV infusion bag"Sources

In January 2025, began in-house sales of ESWANTaihou® OD tablets, Holinart tablets 'Taihou', Parosetron IV injection, and Parosetron IV drip bags.Sources

Start of in-house sales of "Swan Taihou® combined OD tablet", Holinart tablet "Taihou", "ParoNocetron IV", and "ParoNocetron IV infusion bag"Sources

In April 2026, began in-house sales of MS Warm Slip 'Taihou', Mesaderm® ointment 0.1%, Mesaderm® cream 0.1%, and Mesaderm® lotion 0.1%.Sources

Start of in-house sales of MS Warmship "Taihou", "Mesaderm® Ointment 0.1%", "Mesaderm® Cream 0.1%", and "Mesaderm® Lotion 0.1%"Sources

§07

News

18 ARTICLES

Announcement of Natural Symbiosis Site CertificationSources

The natural symbiosis site certification for Okayama Daikou Pharmaceutical's biotope has been announced. The certificate award ceremony, the outlet of the factory's wash and cooling water, and the waterway flowing through the biotope's center are described.

Announcement of Executive Personnel ChangesSources

Okayama Daipō Pharmaceutical Co., Ltd. decided on executive appointments at the regular shareholders' meeting and board of directors meeting held on March 4. Mr. Kenji Yokota was newly appointed as a director overseeing the Pharmaceutical Headquarters, General Affairs Department, and Reliability Assurance Department.

Parosetron formulation, approval of changes to pediatric dosage and administrationSources

Okayama Daiho Pharmaceutical announced that it has obtained approval for pediatric dosage and administration of 'Parosetron IV injection' and 'Parosetron IV infusion bag'.

Notice of Executive Personnel AppointmentSources

Okayama Daipō Pharmaceutical decided on executive personnel at the regular shareholders' meeting and board of directors held on March 6. Mr. Kazu Yoshishige was promoted to President and CEO, and Mr. Fukuichi Ooi was promoted to Executive Director. The Chairman of the Board is Mr. Tatsuya Niki, the Director is Mr. Yōsuke Ishizaki, and the Auditor is Mr. Nobuyuki Hashimoto.

Notice of Discontinuation of New Year's and Summer GreetingsSources

Oka Yamadou Pharmaceutical Co., Ltd. announced that, considering the social situation, it will refrain from sending New Year's cards and summer greetings starting from Reiwa 7 (2025). It requests understanding of the circumstances and apologizes for discontinuing the customary greetings.

Announcement of Executive AppointmentsSources

Okayama Daipō Pharmaceutical decided executive appointments at the regular shareholders' meeting and board of directors held on March 6. The executive composition is Chairman Tatsuya Niki, President and CEO Minehisa Katayama, Directors Koichi Kakigi and Yosuke Ishizaki, and Auditor Nobuyuki Hashimoto.

Announcement of Executive Personnel ChangesSources

Okayama Daipō Pharmaceutical decided on executive appointments at the regular shareholders' meeting and board of directors held on March 10. The president and CEO is Mr. Katayama Mine Shino, the executive director is Mr. Hirata Koichi, the director is Mr. Kakigi Kōichi, and the auditor is Mr. Hashimoto Nobuyuki.

Introduce CO2-Free PowerSources

Oka Yamadake Pharmaceutical introduced CO2-free power from China Power to its headquarters and factory area starting in April 2022. This is expected to reduce annual CO2 emissions by about 2,100 tons, roughly 65% of the 2021 level. The company will continue to work on reducing environmental impact and promoting sustainable development in the local community.

Additional Indication Approval for Eswatainho OD TabletsSources

The oral anticancer agent "Eswatainho OD tablets" has received additional indication approval for adjuvant postoperative chemotherapy in hormone receptor‑positive, HER2‑negative, high‑risk recurrent breast cancer. The same indication has been added to the efficacy and effect section of the package insert.

Obtained Manufacturing and Sales Approval for Palonosetron PreparationsSources

Okayama Daipō Pharmaceutical has obtained manufacturing and sales approval for the 5-HT3 receptor antagonist antiemetic Palonosetron IV injection and Palonosetron IV infusion bag.

§08

Public records

GOV
National Tax Agency basic information9260001021507
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
岡山大鵬薬品株式会社
Trade name (kana)
オカヤマタイホウヤクヒン
Name in English
Corporation type
301
Address
〒705-0024 岡山県備前市久々井字沖1775番地の1
Postal code
7050024
Prefecture code
33
City code
211
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-05-01
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
4847487
METI gBizINFO9260001021507
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
9260001021507
Trade name
岡山大鵬薬品株式会社
Trade name (kana)
オカヤマタイホウヤクヒン
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
岡山県備前市久々井字沖1775番地の1
Postal code
7050024
Prefecture
岡山県
Prefecture code
33
City or district
備前市
City code
211
Street address
久々井字沖1775番地の1
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
Capital
Employees
203
Employees (male)
134
Employees (female)
69
Business summary
医薬品の製造販売
Website URL
http://www.okayama-taiho.co.jp/
Year founded
Business category
E:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-05-01
Key information
9260001021507
§09

Sources & updates

SOURCES
↑